[Critical concentrations for resistances of tubercle bacilli to tuberactinomycin-N, viomycin, capreomycin, and lividomycin in patients treated with these agents (cross-resistance-relationships among resistances to aminoglucoside-antibiotics found during chemotherapy for tuberculosis) (author's transl)].
D000904:Antibiotics, Antitubercular / Q000494:pharmacology*; D002207:Capreomycin / Q000494:pharmacology / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004776:Enviomycin / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D007612:Kanamycin / Q000627:therapeutic use; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D010303:Paromomycin / Q000031:analogs & derivatives / Q000494:pharmacology / Q000627:therapeutic use; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014756:Viomycin / Q000494:pharmacology / Q000627:therapeutic use
D000904:Antibiotics, Antitubercular; D002207:Capreomycin; D007612:Kanamycin; D010303:Paromomycin; D004776:Enviomycin; D014756:Viomycin